The American Cancer Society (ACS) has issued a major update to its prostate cancer screening guidance, moving beyond its previous approach of largely encouraging men to discuss testing with their doctors. The new recommendations set out specific testing intervals based on age and risk, including routine prostate-specific antigen (PSA) blood tests for men at average risk and earlier, more frequent screening for groups facing a higher risk of the disease.

Illustrative image of a middle-aged man discussing prostate cancer screening with a doctor
Illustrative image: a man discusses prostate cancer screening with a healthcare professional.

Announced on November 12, 2026, the update is the society’s first major revision of its prostate cancer screening guideline since 2010. The ACS says stronger evidence now indicates that PSA-based screening can reduce deaths from prostate cancer and the likelihood of diagnosis at an advanced stage. At the same time, improvements in follow-up testing and treatment decisions offer ways to reduce unnecessary biopsies and treatment of cancers that may never become life-threatening.

What The New Screening Guidelines Recommend

For men at average risk, the ACS now recommends a PSA-based screening test every two years between the ages of 50 and 69. Before testing begins, healthcare professionals should explain the potential benefits, limitations and harms so patients can make an informed decision.

The guidance calls for earlier and more frequent screening among men considered to be at higher risk:

  • Black men: Annual PSA-based screening from ages 45 to 69.
  • Men with a strong family history: Annual screening from ages 45 to 69 for non-Black men with a first-degree relative—such as a father, brother or son—diagnosed before age 65, or multiple first-degree relatives diagnosed at any age.
  • Men with one first-degree relative diagnosed at age 65 or older: For non-Black men in this group, screening every two years from ages 45 to 69.
  • Men aged 70 to 74: The decision to continue screening should be individualised after considering general health, life expectancy, personal preferences and possible harms.
  • Men aged 75 and older: Screening is generally not recommended. The ACS also advises against screening men aged 80 and older and men not expected to live at least another 10 years. Some very healthy men aged 75 to 79 may discuss continued testing with a clinician, particularly if PSA levels have been rising.

Why The PSA Blood Test Matters

The PSA test measures the level of prostate-specific antigen, a protein produced by cells in the prostate gland. A blood sample is used to measure PSA levels. Higher-than-expected levels can be associated with prostate cancer, but they do not establish that cancer is present. Benign prostate enlargement, inflammation, infection and other factors can also affect PSA levels.

One important change in the updated guidance is the recommended response to an elevated result. For men aged 45 to 69, a PSA level of 3.0 nanograms per millilitre or higher should be repeated within two weeks to three months. For men aged 70 to 74, the corresponding threshold is 6.5 ng/mL or higher. Repeating the test helps determine whether the elevation persists rather than immediately moving to an invasive procedure.

If an elevated PSA is confirmed, the ACS recommends offering further assessment with prostate magnetic resonance imaging (MRI) and/or a validated biomarker test to help determine whether a biopsy is necessary. A biopsy, in which tissue samples are taken from the prostate, is used to diagnose prostate cancer. The additional steps are intended to help identify men who need further investigation while reducing avoidable biopsies.

Balancing Early Detection With The Risks Of Overdiagnosis

PSA screening has long been debated because it can detect cancers that grow so slowly they may never cause symptoms or shorten a person’s life. Finding such cancers can lead to anxiety, repeated investigations and treatment that may not have been necessary. Prostate cancer treatment can also cause significant side effects, including urinary incontinence, erectile dysfunction and bowel problems.

To address this concern, the updated ACS guideline says active surveillance should be offered as the initial management option for men diagnosed with low-risk prostate cancer. Active surveillance involves carefully monitoring the cancer through scheduled tests and clinical assessments, rather than immediately proceeding to surgery or radiation. Treatment can be considered if later findings indicate that the cancer is becoming more aggressive.

The society’s approach reflects a broader shift towards detecting cancers that are likely to cause harm while avoiding unnecessary intervention for slow-growing disease. The new screening schedule is not a recommendation for every man to undergo the same tests regardless of age, medical history or health status.

Why Black Men And Men With A Family History Are Being Prioritised

The ACS identifies Black men and men with a strong family history as groups that face an elevated risk. According to the society, Black men experience a 67% higher incidence of prostate cancer and nearly twice the mortality rate compared with White men in the United States. Starting screening earlier and testing annually is intended to improve the chance of detecting potentially aggressive disease before it advances.

Family history also matters because having a close relative diagnosed with prostate cancer—particularly at a younger age—can indicate increased risk. Men should tell their healthcare providers about diagnoses among fathers, brothers and sons, including the age at which the relative was diagnosed.

What Men Should Do Now

Men should use the new recommendations as a guide for a conversation with a qualified healthcare professional, not as a substitute for individual medical advice. Anyone considering screening should discuss age, family history, race-related risk, general health, life expectancy and the possible consequences of a positive result.

Men experiencing urinary difficulties, blood in the urine or semen, or persistent bone pain should seek medical assessment rather than waiting for a routine screening appointment. These symptoms can have several causes and do not automatically mean prostate cancer, but they deserve evaluation. Early prostate cancer often causes no symptoms, which is one reason screening is important for men who fall within the recommended age and risk groups.

The new ACS guideline is written for the United States and should not automatically be treated as a national screening policy in every country. Men in Nigeria and elsewhere should discuss locally available testing and their personal risk with a doctor or urologist. Access to PSA testing, follow-up MRI, biopsy and specialist care may differ by location.

A Shift Towards More Structured Screening

The updated recommendations mark a significant change in how the American Cancer Society approaches prostate cancer detection. By setting out regular intervals for average-risk men and earlier testing for higher-risk groups, the organisation is seeking to make early detection more systematic. Its emphasis on repeat testing, MRI or biomarkers, and active surveillance also recognises that screening must be paired with careful decisions about what happens after an abnormal result.

For men in the recommended age groups, the central message is to understand personal risk and make an informed screening plan with a healthcare professional. A PSA result is an early assessment—not a cancer diagnosis—and further evaluation should be guided by clinical advice.

Sources And Further Reading